Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS USA Biotechnology
Market Cap
$136.09 Million
Market Cap Rank
#21387 Global
#7665 in USA
Share Price
$1.79
Change (1 day)
-0.56%
52-Week Range
$1.46 - $65.62
All Time High
$65.62
About

Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder … Read more

Jyong Biotech Ltd. Ordinary Shares - Asset Resilience Ratio

Latest as of June 2025: 44.80%

Jyong Biotech Ltd. Ordinary Shares (MENS) has an Asset Resilience Ratio of 44.80% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$16.88 Million
Cash + Short-term Investments
Total Assets
$37.67 Million
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2023)

This chart shows how Jyong Biotech Ltd. Ordinary Shares's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Jyong Biotech Ltd. Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $16.88 Million 44.8%
Total Liquid Assets $16.88 Million 44.80%

Asset Resilience Insights

  • Very High Liquidity: Jyong Biotech Ltd. Ordinary Shares maintains exceptional liquid asset reserves at 44.80% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Jyong Biotech Ltd. Ordinary Shares Industry Peers by Asset Resilience Ratio

Compare Jyong Biotech Ltd. Ordinary Shares's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
ESSA Pharma Inc
NASDAQ:EPIX
Biotechnology 21.42%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%

Annual Asset Resilience Ratio for Jyong Biotech Ltd. Ordinary Shares (2020–2023)

The table below shows the annual Asset Resilience Ratio data for Jyong Biotech Ltd. Ordinary Shares.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.00% $0.00 $8.25 Million --
2022-12-31 1.07% $94.00K $8.74 Million -18.37pp
2021-12-31 19.44% $1.83 Million $9.43 Million +14.27pp
2020-12-31 5.17% $664.00K $12.84 Million --
pp = percentage points